Imai H, et al. - In an elderly chemotherapy-naive populaion (age ≥70 years) with non-small-cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations (exon 19 deletion or exon 21 L858R mutation), researchers prospectively evaluated the effectiveness and safety of afatinib. Participants were 40 patients (13 men, 27 women) with adenocarcinoma included between May 2014 and August 2017. In this study, for the first time, first-line chemotherapy with afatinib at 30 mg/day was confirmed to be efficacious and feasible in elderly patients with advanced NSCLC harboring sensitive EGFR mutations. The estimated objective overall response was 72.5% and disease control rates were 100%. In addition, the estimated median progression-free survival was 12.9 months; major grade 3 or higher toxicities included diarrhea (12.5%), mucositis (7.5%), and pneumonitis (7.5%).